JPRN-jRCT2080221471未知2 期
A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of S-297995 for the Treatment of Opioid-induced Constipation (OIC) in Cancer Patients
试验速览
- 阶段
- 2 期
- 入组人数
- 212
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Cancer patients with constipation associated with administration of opioid analgesics who meet the following criteria:
- •Patients whose SBM (spontaneous bowel movement) frequency is less than three times per week during the 14 days prior to enrollment, and who experience at least one of the following symptoms of bowel movements;
- •1. Straining during bowel movement
- •2. Feeling of incomplete evacuation
- •3. Passage of hard stools or pellets
排除标准
- •Patients with constipation potentially attributable to causes other than opioid analgesics
- •Patients with hepatic or renal disorders, etc
研究者
相似试验
进行中（未招募）
2 期
Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study (STREAM-AD)Atopic DermatitisJPRN-jRCT2011210072Tanaka Tomoyuki350
进行中（未招募）
不适用
A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease. - SL0007MedDRA version: 9.1Level: LLTClassification code 10042945Term: Systemic lupus erythematosussystemic lupus erythematosusEUCTR2007-002566-35-BECB Inc210
进行中（未招募）
不适用
A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease. - SL0007MedDRA version: 9.1Level: LLTClassification code 10042945Term: Systemic lupus erythematosussystemic lupus erythematosusEUCTR2007-002566-35-LTCB Inc210
进行中（未招募）
不适用
A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease. - SL0007systemic lupus erythematosusEUCTR2007-002566-35-GBCB Inc210
进行中（未招募）
不适用
A Phase IIb Randomized, Double-blind, Placebo-controlled, Dose and Dose Regimen-ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients with Active Disease. - SL0007systemic lupus erythematosusEUCTR2007-002566-35-HUCB Inc210